Tolerability of Asciminib vs Investigator-Selected (IS) Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 ASC4FIRST Study in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

被引：0

作者：

Issa, Ghayas C. ^{[1
]}

Larson, Richard A. ^{[2
]}

Hughes, Timothy P. ^{[3
,4
,5
]}

Hochhaus, Andreas ^{[6
]}

Takahashi, Naoto ^{[7
]}

Bombaci, Felice ^{[8
]}

Wang, Jianxiang ^{[9
,10
]}

Kim, Dong-Wook ^{[11
]}

Dong, Dennis

Kim, Hwan ^{[12
]}

Gu, Ennan ^{[13
]}

Zhang, Yifan ^{[14
]}

Kapoor, Shruti ^{[14
]}

Agrawal, Nithya ^{[14
]}

Jinwal, Rajendra ^{[15
]}

Damon, Andrea ^{[14
]}

Sadek, Islam ^{[14
]}

Cortes, Jorge E. ^{[16
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[2] Univ Chicago, Chicago, IL USA

[3] South Australian Hlth, Adelaide, Australia

[4] Med Res Inst, Adelaide, Australia

[5] Univ Adelaide, Adelaide, Australia

[6] Univ Klinikum Jena, Hematol & Med Oncol, Jena, Germany

[7] Akita Univ, Dept Hematol, Akita, Japan

[8] CML Advocates Network, CML Patients Grp, Turin, Italy

[9] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China

[10] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin, Peoples R China

[11] Uijeongbu Eulji Med Ctr, Uijeongbu Si, South Korea

[12] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[13] Novartis Pharmaceut, Cambridge, MA USA

[14] Novartis Pharmaceut, E Hanover, NJ USA

[15] Novartis Healthcare Pvt Ltd, Hyderabad, India

[16] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

CML; asciminib; chronic myeloid leukemia; chronic phase; treatment patterns; real-world data;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML-345

引用

页码：S368 / S368

页数：1